ShannonNeville(Neville)WestinMD

Obstetrics & Gynecology • Houston, TX

Gynecologic Oncology

Associate Professor Dept of Gynecologic Oncology and Reproductive Medicine

Join to view full profile

Dr. Westin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Westin's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161
Is this information wrong?

Education & Training

University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 2006 - 2010
University of North Carolina HospitalsResidency, Obstetrics and Gynecology, 2002 - 2006
University of Florida College of MedicineClass of 2002

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 2008 - 2026
AZ State Medical License 2023 - 2025
WA State Medical License 2023 - 2025
MS State Medical License 2023 - 2024
GA State Medical License 2023 - 2024
LA State Medical License 2023 - 2024
AL State Medical License 2023 - 2024
TN State Medical License 2023 - 2024
OK State Medical License 2020 - 2024
NC State Medical License 2002 - 2007
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology
Join now to see all

Clinical Trials

Laparoscopic Approach to Cervical Cancer Start of enrollment: 2008 Jan 01
Completed
Not Applicable
Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer Start of enrollment: 2008 Nov 03
Active, not recruiting
Phase 2
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer Start of enrollment: 2010 Aug 19
Active, not recruiting
Phase 1
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer Start of enrollment: 2012 Sep 01
Completed
Phase 1
Biospecimen Collection in Assessing the Effect of Trametinib With or Without Uprosertib on Biomarkers in Patients With Persistent or Recurrent Endometrial Cancer Enrolled on Trial GOG02290 Start of enrollment: 2004 Aug 13
Completed
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Start of enrollment: 2014 Nov 11
Active, not recruiting
Phase 1, Phase 2
Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2016 Feb 04
Active, not recruiting
Early Phase 1
Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer Start of enrollment: 2016 Aug 24
Completed
Phase 2
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur) Start of enrollment: 2016 Jul 06
Active, not recruiting
Phase 1, Phase 2
Selumetinib and Olaparib in Solid Tumors Start of enrollment: 2017 Aug 04
Active, not recruiting
Phase 1
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2019 Apr 29
Active, not recruiting
Phase 1
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery Start of enrollment: 2019 Jun 07
Active, not recruiting
Early Phase 1
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer Start of enrollment: 2020 May 05
Active, not recruiting
Phase 3
Prediction of Recurrence Among Low Risk Endometrial Cancer Patients Start of enrollment: 2012 Nov 08
Recruiting
EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors Start of enrollment: 2015 Jul 01
Recruiting
Phase 1
Roles: Principal Investigator, Contact
TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Start of enrollment: 2021 Dec 14
Active, not recruiting
Early Phase 1
Roles: Principal Investigator, Contact
Etigilimab and Nivolumab for the Treatment of Platinum-Resistant Recurrent Clear Cell Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2021 Oct 01
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2018 Dec 07
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer Start of enrollment: 2015 Sep 23
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer Start of enrollment: 2023 Mar 24
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer Start of enrollment: 2023 Jul 12
Recruiting
Phase 1
Roles: Principal Investigator, Contact
A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary Start of enrollment: 2022 Dec 09
Terminated
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent: Final Results from a Phase II Study.
Madeline T Olson, Brian Madajewski, Brian Ostrander, Kartik Krishnan, Patrick Wagner, Edward A Levine, Alex C Kim, Perry Shen, Nicole D Fleming, Shannon N Westin, Laur...> ;Annals of Surgical Oncology. 2024 Apr 15
Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis.
Anne Knisely, Emily Hinchcliff, Bryan Fellman, Ann Mosley, Kathryn Lito, Sara Hull, Shannon N Westin, Anil K Sood, Kathleen M Schmeler, Jolyn S Taylor, Steven Y Huang,...> ;Med. 2024 Apr 12
Neuroendocrine neoplasms of the ovary: a review of 63 cases.
Alejandra Flores Legarreta, Reem Saab, Naomi R Gonzales, Gary B Chisholm, Shannon N Westin, R Tyler Hillman, Michael Frumovitz> ;International Journal of Gynecological Cancer. 2024 Apr 1
EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer.
Joseph, R., Dasari, S., Umamaheswaran, S., Mangala, L., Bayraktar, E., Rodriguez-Aguayo, C., Wu, Y., Nguyen, N., Powell, R., Sobieski, M., Liu, Y., Kim, M., Corvigno, ...> ;International Journal of Molecular Sciences. 2024 Jan 20
Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors.
Legarreta, A., Fellman, B., Foster, K., Vuttaradhi, V., Brodsky, A., Hillman, R., How, J., Handley, K., Glassman, D., Lawson, B., Westin, S., Ramondetta, L., Gershenso...> ;American Journal of Obstetrics and Gynecology. 2024 Jan 6
PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibition.
Li, Y., Dobrolecki, L., Sallas, C., Zhang, X., Kerr, T., Bisht, D., Wang, Y., Awasthi, S., Kaundal, B., Wu, S., Peng, W., Mendillo, M., Lu, Y., Jeter, C., Peng, G., Li...> ;Cell Reports. Medicine. 2023 Dec 19
1 citations
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.
Emily M Hinchcliff, Anne Knisely, Naomi Adjei, Bryan Fellman, Ying Yuan, Ami Patel, Cai Xu, Shannon N Westin, Anil K Sood, Pamela T Soliman, Aaron Shafer, Nicole D Fle...> ;Cancer. 2024 Apr 1
Ischemic bowel associated with newly diagnosed patent foramen ovale.
Hannah Hong, Deanna Glassman, Shannon Neville Westin> ;International Journal of Gynecological Cancer. 2023 Nov 6
1 citations
The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches.
Dimitrios Nasioudis, Marta Llaurado Fernandez, Nelson Wong, Daniel J Powell Jr, Gordon B Mills, Shannon Westin, Amanda N Fader, Mark S Carey, Fiona Simpkins> ;Gynecologic Oncology. 2023 Oct 1
2 citations
Low-grade serous ovarian cancer: expert consensus report on the state of the science.
Rachel N Grisham, Brian M Slomovitz, Nicole Andrews, Susana Banerjee, Jubilee Brown, Mark S Carey, Herman Chui, Robert L Coleman, Amanda N Fader, Stephanie Gaillard, C...> ;International Journal of Gynecological Cancer. 2023 Sep 4
8 citations
Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer.
Xudong Zhang, Jun Yao, Xiaoran Li, Na Niu, Yan Liu, Richard A Hajek, Guang Peng, Shannon Westin, Anil K Sood, Jinsong Liu> ;Science Advances. 2023 Jul 21
1 citations
Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer.
Javier Leo, Eleonora Dondossola, Kaitlin J Basham, Nathaniel R Wilson, Omar Alhalabi, Jianjun Gao, Katherine C Kurnit, Michael G White, Jennifer L McQuade, Shannon N W...> ;Endocrinology. 2023 Apr 17
3 citations
Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers.
Van K Morris, Amir Jazaeri, Shannon N Westin, Curtis Pettaway, Solly George, Ryan W Huey, Michaela Grinsfelder, Aaron Shafer, Benny Johnson, David Vining, Ming Guo, Br...> ;The Oncologist. 2023 Jul 5
2 citations
Outcomes of patients with therapy-related myeloid neoplasms after treatment with poly(ADP-ribose) polymerase proteins inhibitors for solid tumours.
Emmanuel Almanza-Huante, Alex Bataller, Samuel Urrutia, Georgina Gener-Ricos, Robert Edward Briski, Rashmi Kanagal-Shamanna, Karen H Lu, Shannon N Westin, Timothy A Ya...> ;British Journal of Haematology. 2023 May 1
1 citations
Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors.
Katherine I Foster, Alejandra Flores Legarreta, Rhea Kamat, Katelyn F Handley, Deanna Glassman, Jeffrey A How, Barrett C Lawson, Shannon N Westin, Lois M Ramondetta, M...> ;American Journal of Obstetrics and Gynecology. 2023 Jun 1
1 citations
Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer.
Deanna Glassman, Mark S Kim, Meredith Spradlin, Sunil Badal, Mana Taki, Pratip Bhattacharya, Prasanta Dutta, Charles V Kingsley, Katherine I Foster, Olamide Animasahun...> ;Iscience. 2023 Feb 17
4 citations
Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer.
Santosh K Dasari, Robiya Joseph, Sujanitha Umamaheswaran, Lingegowda S Mangala, Emine Bayraktar, Cristian Rodriguez-Aguayo, Yutuan Wu, Nghi Nguyen, Reid T Powell, Mary...> ;International Journal of Molecular Sciences. 2023 Feb 15
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer.
Son, J., Lin, H., Fu, S., Biter, A., Dumbrava, E., Karp, D., Naing, A., Pant, S., Piha-Paul, S., Rodon, J., Subbiah, V., Tsimberidou, A., Yap, T., Frumovitz, M., Jazae...> ;Journal of Immunotherapy and Precision Oncology. 2023 Feb 1
Clinical Application of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Ovarian Cancer.
Melissa M Pham, Monica Avila, Emily Hinchcliff, Shannon N Westin> ;Cancer Treatment and Research. 2023 Jan 1
3 citations
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expans...
Shannon N Westin, Siqing Fu, Apostolia Tsimberidou, Sarina Piha-Paul, Fechukwu Akhmedzhanov, Bulent Yilmaz, Lacey McQuinn, Amanda L Brink, Jing Gong, Cheuk Hong Leung,...> ;Gynecologic Oncology. 2023 Jan 1
1 citations
Targeting the PI3K Pathway in Gynecologic Malignancies.
Monica Avila, Michaela Onstad Grinsfelder, Melissa Pham, Shannon N Westin> ;Current Oncology Reports. 2022 Dec 1
3 citations
Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study.
Katherine C Kurnit, Silvana Pedra Nobre, Bryan M Fellman, David A Iglesias, Kristina Lindemann, Anuja Jhingran, Ane Gerda Z Eriksson, Beyhan Ataseven, Gretchen E Glase...> ;Gynecologic Oncology. 2022 Dec 1
6 citations
Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics.
Katelyn F Handley, Travis T Sims, Nicholas W Bateman, Deanna Glassman, Katherine I Foster, Sanghoon Lee, Jun Yao, Hui Yao, Bryan M Fellman, Jinsong Liu, Zhen Lu, Kelly...> ;JAMA Network Open. 2022 Oct 3
7 citations
Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex.
Yu-Yi Chu, Mei-Kuang Chen, Yongkun Wei, Heng-Huan Lee, Weiya Xia, Ying-Nai Wang, Clinton Yam, Jennifer L Hsu, Hung-Ling Wang, Wei-Chao Chang, Hirohito Yamaguchi, Zhou ...> ;Nature Cancer. 2022 Oct 1
3 citations
Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.
David M Gershenson, Lauren P Cobb, Shannon N Westin, Yingao Zhang, Amir Jazaeri, Anais Malpica, Charlotte C Sun> ;Gynecologic Oncology. 2022 Nov 1
Join now to see all

Journal Articles

Prospective Phase II Trial of Levonorgestrel Intrauterine Device: Non-Surgical Approach for Complex Atypical Hyperplasia and Early Endometrial Cancer
Shannon N Westin, Lois M Ramondetta, Kathleen M Schmeler, Pamela T Soliman, Nicole D Fleming, Jennifer K Burzawa, Alpa M Nick, Andrea M Milbourne, Diane C Bodurka, Rob..., American Journal of Obstetrics and Gynecology

Lectures

Risk factors for progression or death in ovarian cancer patients who completed first-line platinum treatment.
2019 ASCO Annual Meeting - 6/1/2019
Phase I trial of olaparib (PARP inhibitor) and vistusertib (mTORC1/2 inhibitor) in recurrent endometrial, ovarian and triple negative breast cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018
Tumor Sequencing: Who, What, When, and Why to Order Tumor Mutation Analysis
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Authored Content

Prospective Phase II Trial of Levonorgestrel Intrauterine Device: Non-Surgical Approach for Complex Atypical Hyperplasia and Early Endometrial CancerAugust 2020
Prospective Phase II Trial of Levonorgestrel Intrauterine Device: Non-Surgical Approach for Complex Atypical Hyperplasia and Early Endometrial CancerAugust 2020

Press Mentions

Peritumoral Anesthetic Infiltration Impacts Survival in Early Breast CancerMay 11th, 2023
These Tiny Beads May Offer Big Hope to Ovarian Cancer PatientsApril 3rd, 2023
Novel Strategies Show Winning Potential in Ovarian CancerMarch 28th, 2023
Join now to see all